Jen Wieczner

Stay informed with Jen Wieczner’s coverage and analysis for Fortune.

Page 47 of 51

  • Television crews wait outside the address where Nav Sarao Futures Limited is registered, in Hounslow, LondonFinance

    This is how much money the arrested trader made on the ‘flash crash’

    By
  • PA: Mylan HeadquartersFinance

    Mylan plays monkey-in-the-middle of hostile takeover battles

    By
  • Frederick's of Hollywood Third Annual Lingerie Auction to Benefit The TS AllianceRetail

    Bra retailer Frederick’s of Hollywood goes bust

    By
  • A TWC truck.Tech

    Government lawyers don’t want Comcast and Time Warner Cable to merge

    By
  • FRANCE-ENERGY-GEFinance

    Why GE could retake throne as king of all dividend stocks

    By
  • Finance

    Biotech “bubble” popped, time to buy again?

    By

  • Tesla investors do the electric slide

    By
  • George Scangos, CEO of Biogen Inc. speaks during Reuters Health Summit in New YorkFeatures

    How Biogen scored the most successful Alzheimer’s drug so far

    By
  • Tech

    Biotech pros’ top 8 stock picks

    By
  • MPW

    Clinton Foundation appoints Donna Shalala as new leader

    By
  • Many of WeWork’s offices offer creative distractions.Leadership

    WeWork’s utopian vision of your future life—in the office

    By
  • FRANCE-AGRICUTLURE-PIG-FARMFinance

    This is the only commodity to fall more than oil

    By
  • IL: Corporations In IllinoisFinance

    Fat Pharma: Pfizer-Hospira and the top 10 overpriced drug deals ever

    By
  • Earns PfizerFeatures

    In speed mode, FDA approves Pfizer’s big new drug early

    By
  • J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, QuebecFinance

    After Allergan loss, is Valeant dumpster diving?

    By